Analysts have provided varying ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) over the last quarter, with a total of 13 ratings ranging from bullish to bearish. The average 12-month price target for ACAD is $34.08, with a high estimate of $42.00 and a low estimate of $25.00, marking a 13.15% increase from the previous average of $30.12. Several analysts have raised their price targets and ratings, indicating a positive outlook on the company's performance. ACADIA Pharmaceuticals is a biotech company focusing on CNS disorders and has shown a revenue growth rate of 61.96% as of September 30, 2023, but with a net margin of -30.79% and an ROA of -10.22%. The company's market capitalization is below the industry average, and it has a debt-to-equity ratio of 0.16.